RB1 and breast carcinoma: As one might expect given their mechanism of action, CDK4/6 inhibitors induce cytostasis (G1 cell cycle arrest) in RB-proficient luminal breast cancer cells in vitro (Fig. 2A) [4, 5, 33–36].